Retatrutide Research Peptide — Buy Triple Receptor Agonist GLP-1/GIP/Glucagon (≥97% Purity)
Retatrutide (CAS 2381272-15-5) is a next-generation synthetic peptide engineered as a triple co-agonist at the GLP-1R, GIPR, and glucagon receptor (GCGR). Representing the leading edge of incretin pharmacology research, retatrutide builds on the dual-agonist mechanism of tirzepatide by adding glucagon receptor activity — enabling investigation into the additive metabolic effects of all three incretin axes simultaneously. It is among the newest and most sought-after research peptides in metabolic biology.
Mechanism of Action
Retatrutide activates three complementary GPCRs: GLP-1R drives insulin secretion and appetite suppression; GIPR augments insulin response and modulates adipose tissue; GCGR activation increases hepatic glucose output, promotes lipolysis, and raises energy expenditure. The net effect in research models involves substantial changes in energy balance, lipid mobilization, and glucose homeostasis — providing a uniquely comprehensive tool for studying multi-receptor metabolic regulation.
Research Applications
- Triple incretin receptor co-agonism and signaling studies
- Hepatic glucose output and glycogenolysis research
- Lipolysis, fat mobilization, and adipose tissue biology
- Energy expenditure and thermogenesis models
- Comparative single vs. dual vs. triple receptor agonism studies
Specifications
- Chemical Name: Retatrutide
- CAS Number: 2381272-15-5
- Molecular Weight: ~4,759 Da
- Purity: ≥97% (HPLC verified)
- Form: Lyophilized powder
- Available Sizes: 2mg, 5mg, 10mg
Storage & Handling
Store lyophilized retatrutide at −20°C away from moisture and light. Reconstitute with bacteriostatic water and store at 4°C for up to 28 days. Avoid repeated freeze-thaw cycles. Use under sterile conditions by trained research personnel only.
For in-vitro laboratory research use only. Not for human or animal consumption. Not a drug, supplement, or medicinal product.
